Walsorab-D Capsule SR is a combination medication containing Domperidone 30mg and Rabeprazole 20mg, formulated for sustained release to provide prolonged therapeutic effects. Domperidone is a peripheral dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, leading to a significant reduction in gastric acidity. The combined action of these agents makes Walsorab-D Capsule SR effective in the management of gastroesophageal reflux disease (GERD), dyspepsia, and other acid-related gastrointestinal disorders where delayed gastric emptying and acid hypersecretion coexist. This formulation is particularly beneficial for patients experiencing symptoms like heartburn, regurgitation, and upper abdominal discomfort. Walsorab-D should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with underlying cardiac conditions or those taking medications that may interact with domperidone or rabeprazole.